- $126.16m
- $125.99m
- $61.86m
Brief: Journey Medical Corporation Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi™ (Dfd-29) To Treat Rosacea
U.S. STOCKS ON THE MOVE-Journey Medical, Freshpet, Fox
Journey Medical gains as US FDA approves skin condition drug
FDA approves Journey Medical's drug for long-term skin condition (updated)
FDA approves Journey Medical's drug for long-term skin condition
Journey Medical Corp expected to post a loss of 14 cents a share - Earnings Preview
Brief: Journey Medical Says On July 9, Got Into Amendment To That Certain Credit Agreement Dated Dec 27, 2023
Journey Medical Corp reports results for the quarter ended in March - Earnings Summary
Brief: Journey Medical Corporation Appoints Joseph Benesch As Chief Financial Officer
Journey Medical Corp reports results for the quarter ended in December - Earnings Summary
Brief: Journey Medical Corporation Announces U.S. FDA Acceptance Of New Drug Application For DFD-29 For The Treatment Of Rosacea
Journey Medical Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: Journey Medical Corporation Secures Credit Facility With SWK Holdings For Up To $20 Million
Brief: Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
Fortress Biotech shares plunge after highly dilutive offering
Journey Medical Corp expected to post a loss of 15 cents a share - Earnings Preview
Brief: Jasper Therapeutics Inc - Bill Lis Is Stepping Down As Chairperson
Brief: Journey Medical Announces Data from Bioavailability Study of DFD-29 vs Solodyn
Brief: Journey Medical Says Was Formally Notified By Nasdaq That It Has Determined Company Complies With Stockholders' Equity Requirement